Yan Li

Summary

Affiliation: AstraZeneca R and D

Publications

  1. ncbi In vitro assessment of metabolic drug–drug interaction potential of AZD2624, neurokinin-3 receptor antagonist, through cytochrome P(450) enzyme identification, inhibition, and induction studies
    Yan Li
    Discovery DMPK, AstraZeneca Pharmaceuticals, Wilmington, Delaware, USA
    Xenobiotica 40:721-9. 2010
  2. ncbi Disposition and metabolism of ticagrelor, a novel P2Y12 receptor antagonist, in mice, rats, and marmosets
    Yan Li
    Drug Metabolism and Pharmacokinetics, AstraZeneca R and D, Waltham, MA 02451, USA
    Drug Metab Dispos 39:1555-67. 2011
  3. ncbi Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development
    Richard A Thompson
    Discovery DMPK, AstraZeneca R and D Molndal, SE 413 83 Mölndal, Sweden
    Chem Biol Interact 192:65-71. 2011

Collaborators

  • Scott W Grimm
  • Diansong Zhou
  • Richard A Thompson
  • Richard Weaver
  • Hugues Dolgos
  • Lars Weidolf
  • Ken Page
  • Alf Claesson
  • Ian Wilson
  • Emre M Isin
  • J Gerry Kenna

Detail Information

Publications3

  1. ncbi In vitro assessment of metabolic drug–drug interaction potential of AZD2624, neurokinin-3 receptor antagonist, through cytochrome P(450) enzyme identification, inhibition, and induction studies
    Yan Li
    Discovery DMPK, AstraZeneca Pharmaceuticals, Wilmington, Delaware, USA
    Xenobiotica 40:721-9. 2010
    ..However, metabolism of AZD2624 might be inhibited when co-administrated with potent CYP3A4/5 inhibitors...
  2. ncbi Disposition and metabolism of ticagrelor, a novel P2Y12 receptor antagonist, in mice, rats, and marmosets
    Yan Li
    Drug Metabolism and Pharmacokinetics, AstraZeneca R and D, Waltham, MA 02451, USA
    Drug Metab Dispos 39:1555-67. 2011
    ..Ticagrelor, AR-C124910, and AR-C133913 were the major components found in feces from the three species examined. Overall, in vivo metabolite profiles were qualitatively similar across all species and consistent with in vitro results...
  3. ncbi Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development
    Richard A Thompson
    Discovery DMPK, AstraZeneca R and D Molndal, SE 413 83 Mölndal, Sweden
    Chem Biol Interact 192:65-71. 2011
    ..We exemplify the potential value of this approach by consideration of the thiazolidinedione class of drugs...